Influx Healthtech Reports Robust H1 FY27 Growth and Targets Capacity-Driven Expansion
Influx Healthtech Ltd · Transcript · 09 Nov 2026, 5:59 pm
Influx Healthtech Reports Robust H1 FY27 Growth and Targets Capacity-Driven Expansion Influx Healthtech reported H1 FY27 revenue of INR85.4 cr, up 27.9% YoY, driven primarily by nutraceuticals (INR75.3 cr). EBITDA rose 25.2% YoY to INR18.3 cr with margins at 21.5%, while PAT grew 20% YoY to INR12 cr. The company incurred INR19.9 cr in Capex. Its new 75,000 sq ft facility is slated for operationalization around Jan'27, expanding capacity by 2.5x and targeting INR400–500 cr in peak revenue by FY28–FY29. Management reiterated a FY27 revenue growth target of 25%, aiming to cross INR200 cr.
Original exchange filing (PDF)
More announcements from Influx Healthtech Ltd
- Influx Healthtech Limited has informed the Exchange about Link of Recording of Investor Conference Call held on November 5, 2026 · 05 Nov 2026
- Influx Healthtech Limited has informed the Exchange about Investor Presentation · 05 Nov 2026
- Influx Healthtech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
- Influx Healthtech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 04 Nov 2026
- Influx Healthtech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 04 Nov 2026
- Influx Healthtech Limited has informed the Exchange about Schedule of Investor Conference Call · 05 Nov 2026
- INFLUX HEALTHTECH LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 04 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 04 Nov 2026
